Characterizing a Clinical Trial – Representative, Real-World Population with Heart Failure with Reduced Ejection Fraction
Quinn S Wells,Eric Farber-Eger,Loren Lipworth,Paul Dluzniewski,Ricardo Dent,John Umeijiego,Sarah S Cohen
DOI: https://doi.org/10.2147/CLEP.S341919
2022-01-13
Clinical Epidemiology
Abstract:Quinn S Wells, 1, 2 Eric Farber-Eger, 1, 2 Loren Lipworth, 2, 3 Paul Dluzniewski, 4 Ricardo Dent, 4 John Umeijiego, 4 Sarah S Cohen 3, 5 1 Division of Cardiovascular Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA; 2 Vanderbilt Translational and Clinical Cardiovascular Research Center (VTRACC), Vanderbilt University Medical Center, Nashville, TN, USA; 3 Division of Epidemiology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA; 4 Center for Observational Research, Amgen, Inc., Thousand Oaks, CA, USA; 5 Epidstrategies, A Division of Toxstrategies, Inc., Cary, NC, USA Correspondence: Sarah S Cohen Tel +1 919-885-0548 Email Purpose: Given known differences between real-world and clinical trial populations, we characterized demographics, clinical characteristics, and outcomes using real-world (RW) data for patients with heart failure with reduced ejection fraction (HFrEF), including those similar to subjects enrolled in an HFrEF clinical trial to better understand patient populations that could benefit from novel therapies. Patients and Methods: Using Vanderbilt University Medical Center electronic health records (2006– 2019), two RW cohorts of HFrEF patients were identified. The "Clinical Cohort" was based on a validated HFrEF algorithm and left ventricular ejection fraction (LVEF) ≤ 40%. The "GALACTIC-HF-like Cohort" mirrored enrollment requirements of the GALACTIC-HF clinical trial including hospitalizations, medications, laboratory values, and LVEF ≤ 35%. Results: Median age at index for the Clinical Cohort (N = 3954) and GALACTIC-HF-like Cohort (N = 1541) were 65 and 61 years, respectively; both were 67% male and 80% white. Over half had coronary artery disease (55% Clinical vs 64% GALACTIC-HF-like); hypercholesterolemia was common (69% Clinical vs 74% GALACTIC-HF-like). Chronic kidney disease (31 vs 21%), atrial fibrillation (32 vs 29%), and cardiac resynchronization or implantable cardioverter defibrillator (26 vs 23%) were higher in the GALACTIC-HF-like Cohort. ACE inhibitor use was high in both groups but more common in the GALACTIC-HF-like Cohort (71% and 82%, respectively). Beta-blockers or loop diuretics were used by > 90% of both cohorts. HF hospitalization rates were 261 (95% CI 224, 297) per 1000 person-years in Clinical versus 523 (484, 562) in GALACTIC-HF-like Cohort (median follow-up of 2.9 and 4.2 years, respectively). Conclusion: Approximately 40% of RW HFrEF patients met criteria for the GALACTIC-HF trial. While findings of ongoing clinical trials may be directly generalizable to this sizable proportion of patients, future trials should examine whether the majority of patients with lower prevalence of comorbidities and rate of HF hospitalization could benefit from emerging HF treatments. Keywords: heart failure, reduced ejection fraction, real-world evidence, electronic health record Real-world data are needed to characterize patient populations with heart failure with reduced ejection fraction (HFrEF) that could benefit from novel therapies. Using the Vanderbilt University Medical Center electronic health records, we identified a clinical cohort based on a validated HFrEF algorithm, as well as a second cohort selected to mirror enrollment requirements of the GALACTIC-HF clinical trial based on hospitalizations, medications, laboratory and other clinical values. Approximately 40% of RW HFrEF patients met criteria for the GALACTIC-HF trial. While findings of ongoing clinical trials may be directly generalizable to this sizable proportion of patients, whether the majority of patients with lower prevalence of comorbidities and rate of HF hospitalization could benefit from emerging HF treatments should be considered in future trials. Heart failure with reduced ejection fraction (HFrEF) affects at least 3 million Americans 1,2 and, despite recent therapeutic advances, remains a clinical challenge, with annual mortality above 25%. To date, there are no safe medical therapies that directly address the fundamental pathology of impaired cardiac contractility at the level of the cardiac sarcomere. 3 The public health burden of HFrEF has made it a high priority for therapeutic development, and many new therapeutics are now being evaluated in ongoing clinical trials. 4 Gauging the external validity of clinical trials can be challenging because individuals enrolled into studies may be highly selected. 5 Ultimately, the potential impact of any novel therapeutic 6 agent is determined by the number of patients eligible to receive it -Abstract Truncated-
public, environmental & occupational health